High Flow Oxygen Therapy Versus Conventional Oxygen Therapy in Cardiac Surgery Patients

High Flow Oxygen Therapy Versus Conventional Oxygen Therapy in Cardiac Surgery Patients-OPTICAR Study

High flow oxygen therapy has been applied after extubation in cardiac surgery patients with uncertain efficacy. The current authors plan to conduct a prospective, randomized, controlled study of nasal high flow therapy (NHF) application with high (60L/min) or low flow (40L/min) oxygen mixture administration versus standard oxygen treatment (Venturi mask) after extubation of patients undergoing elective or non-elective cardiac surgery.

Study Overview

• Status: Completed
• Conditions: Hypoxemic Respiratory Failure
• Intervention / Treatment: Device: Nasal Cannula High Flow Oxygen

Detailed Description

Over the past decade, nasal high flow (NHF) has been introduced for oxygen therapy in adults. Its indications have been expanded, especially in cases of acute hypoxemic respiratory failure.

The device consists of an air/oxygen blender connected via an active heated humidifier to a nasal cannula, through a single limb, heated inspiratory circuit. It delivers a fraction of inspired oxygen (FiO2) from 21% to 100% with a flow rate up to 60 L/min. FiO2 adjustments are independent of the set flow rate so that the patient is given heated, humidified high-flow oxygen, with a flow that can be adjusted above the patient's maximum inspiratory flow rate, thereby increasing confidence about the actual FiO2 being delivered to the patient. These device characteristics make it more promising in comparison with conventional low- and high-flow oxygen devices (e.g., nasal cannula, non-rebreathing masks, Venturi masks), especially in patients with high inspiratory flow rates, such as patients with acute respiratory failure (ARF).

The benefits arising from application of oxygen with high flow rates via NHF are

1. reduction in the entrainment of room air and thus ensuring higher and more stable FiO2 values,
2. generation of positive airway pressures during expiration as a result of the expiratory resistance imposed to the patient's exhalation against the continuous high flow of incoming oxygen gas,
3. improving mucociliary function and clearance of secretion by continuous heating and humidifying of the administered gas,
4. reducing dead space ventilation and
5. reducing work of breathing. All the aforementioned NHF mechanisms of actions exert various effects on the respiratory system, including improved gas exchange, lower respiratory rate and effort and improved lung mechanics which are correlated with more comfort and less subjective dyspnea.

Respiratory complications after cardiac surgery can affect morbidity and mortality, and increase the healthcare cost. Advanced age, duration of extracorporeal circulation, history of significant underlying cardiac or pulmonary disease and phrenic nerve injury are the main prognostic factors for post cardiac surgery respiratory complications.

Traditionally, low- and high-flow oxygen systems are used to reverse postsurgical respiratory complications with or without addition of continuous (CPAP) or bi-level (NIV) positive airway pressure.

NHF might be superior for the prevention or treatment of those respiratory complications, since it can provide high-flow of heated and hydrated oxygen while the positive airway pressure created by the high gas flow can recruit alveoli and increase the end-expiratory lung volume.

Studies applying NHF immediately after extubation in cardiac surgery patients revealed better oxygenation and less need for advanced methods of respiratory support compared to conventional oxygen devices , and similar results compared to noninvasive ventilation. However, Zochios et al, summarized all the available up to date data of NHF compared to conventional oxygen devices and non-invasive ventilation in patients undergoing cardiothoracic surgery and they did not find any further benefit by NHF use. The aforementioned discrepancy could be explained by the differences in the studied populations and NHF flow settings. The proposed initial flow rate differs among the studies, with some authors suggesting initial lower flows (35-40 L/min) that will be better tolerated by the patients and others suggesting initial maximal flows (60 L/min) to rapidly relieve dyspnea and prevent muscle fatigue.

Aim The primary goal of the study is to evaluate the efficacy of NHF (with initial flows of 60 L/min or 40 L/min) versus conventional oxygen systems on respiratory parameters (respiratory rate, pO2/ FiO2, spO2, use of accessory muscles, dyspnoea, comfort and tolerance by using the visual analogue scale) immediately after the extubation of cardiac surgery patients.

Additional goals of the study are to compare two different initial NHF flows of 60 L/min and 40 L/min, ICU Length of Stay, Hospital Length of Stay, rates of ICU re-admission and re-intubation and any other respiratory / non-respiratory complications and adverse events. Moreover, the rate of failure of the initial treatment will be recorded (as a major measure of treatment efficacy).

Method

This is a prospective, non-blinded, randomized study in post-extubated cardiac surgery patients. The study population will consist of three patient groups:

The first group (Study Group 1) will include patients on NHF with initial settings of FiO2=60% and gas flow=60L/min.

The second group (Study Group 2) will include patients on NHF with initial settings of FiO2=60% and gas flow=40L/min In the third group (control group) all patients will receive oxygen therapy according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.

Patients in both study groups would be weaned off the NHF as follows; First reducing FiO2 gradually to 50%, and then gradually reducing the gas flow (either from 60l/min or 40/min, depending on the study group) down to 30l/min, aiming at the final wean-off goal of 20l/min, unless the attending physician decides to wean-off patient to Venturi mask directly from a higher gas flow supply (e.g.: 30-25l/min) Treatment failure will be defined as any crossover from one treatment to another due to patient's respiratory distress and discomfort. To be more specific, switch of gas flow from 40L/min to 60L/min, crossover from either NHF group to standard practice (Venturi mask) or need for more advanced respiratory support such as non-invasive ventilation or invasive mechanical ventilation.

Any implemented treatment would also be defined as "failure" when any irreversible (for at least 48 hours) FiO2/gas-mixture flow escalation might be needed, either it is being recorded on Study group 1 & 2 or Control group.

An initial power analysis was based on a predicted, average failure rate of 15% in the 2 NHF groups and a failure rate of 51% in the control group; this analysis yielded the need for enrollment of a total of 41 NHF patients and 21 controls for alpha = 0.05 and power=0.80. To ensure equal numbers of patients in each one of the 2 NHF groups, the authors decided to actually enroll 42 NHF patients (n=21 for each NHF group) and 21 controls, resulting in a total enrollment of 63 patients. At one year after study initiation, actual, total enrollment amounted to 45 patients. At this time point, the Data Monitoring Committee (after confirming the safe application of the study protocol) recommended the continuation of the study until the enrollment of 99 patients (n=33 for each one of the 3 groups); the rationale for this was to compensate for possible dropouts and/or missing data (especially for the secondary and "other" outcomes). Accordingly, the study was completed with an actual enrollment of 99 patients.

• Study Type: Interventional
• Enrollment (Actual): 99
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Greece
  • Attiki
    • Athens, Attiki, Greece, 10676
      • Evangelismos General Hospital of Athens

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Cardiac ICU adult patients
• >18 years
• After elective or urgent cardiac surgery
• Successful Spontaneous Breathing Trial (SBT) with T-piece and FiO2=60%.
• pO2/ FiO2 <200
• Hemodynamically stable (160>SAP>90mmHg)

Exclusion Criteria:

• Obstructive Sleep Apnea Syndrome supported by CPAP
• COPD, officially diagnosed, respiratory failure with serum blood ph <7,35.
• Patients with tracheostomy,
• DNR status,
• Glasgow Coma Scale score < 13,
• Insufficient knowledge of Greek Language
• Visual or hearing impairment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Study Group 1; The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment. The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min.	Device: Nasal Cannula High Flow Oxygen; Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
Active Comparator: Study Group 2; The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment. The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min.	Device: Nasal Cannula High Flow Oxygen; Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
No Intervention: Control group; In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min. In this group all patients will receive the usual standard of care, with no other interventions included

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Successful weaning (i.e. absence of treatment failure) from Nasal Cannula High Flow Oxygenation post extubation from cardiac surgery within at least 48 hours	Successful weaning (i.e. absence of treatment failure as further described in methods) would be defined as = 0 when there would be avoided successfully any alternation with other mode of oxygen therapy, or re-intubation, or Non Invasive Ventilation. For all groups: Unsuccessful weaning (i.e. actual treatment failure as further described in methods) would be defined as =1 when there would not be avoided any alternation with other oxygen therapy, re-intubation, Non Invasive Ventilation	Up to at least 48 hours post extubation or until ICU discharge (predicted cardiothoracic ICU stay could occasionally extend up to 7 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Successful maintenance of Respiration rate within normal range (12-20/min) on initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation	Successful maintenance of Respiratory rate within normal range would be defined as = 0. Unsuccessful (=1) if exceeds normal range (12-20/min). Continuous monitoring and recording of implementation of air flow at 60L/min with Nasal Cannula High Flow Oxygenation	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Successful maintenance of Respiration rate within normal range (12-20/min) on initial air flow of 40 L/min with Nasal Cannula High Flow Oxygenation	Successful maintenance of Respiratory rate within normal range would be defined as = 0. Unsuccessful (=1) if exceeds normal range (12-20/min). Continuous monitoring and recording of implementation of air flow at 40L/min with Nasal Cannula High Flow Oxygenation	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Recording of pO2/FiO2 ratio with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation	Continuous monitoring of implementation initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation	Post extubation period up to 48 hours or ICU discharge
Recording of pO2/FiO2 ratio with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation	Continuous monitoring of implementation initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Recording of pO2/FiO2 ratio with Venturi mask FiO2: 60%, 15L/min	Continuous monitoring of implementation Venturi mask, FiO2: 60%, 15L/min	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Successful maintenance of saturation O2 in Hemoglobulin within normal range with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation	Successful maintenace of saturation O2 in Hemoglobulin > 92% would be defined as = 0. If saturation O2 < 92 %, then it would be definded as Unsuccessful = 1 Continuous monitoring and recording of implementation initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Successful maintenance of saturation O2 in Hemoglobulin within normal range with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation	Successful maintenance of saturation O2 in Hemoglobulin within normal range would be defined as = 0. If saturation O2 < 92 %, then it would be definded as Unsuccessful = 1 Continuous monitoring and recording of implementation initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Successful maintenance of saturation O2 in Hemoglobulin within normal range with Venturi mask, FiO2: 60%, 15L/min	Successful maintenance of saturation O2 in Hemoglobulin > 92% would be defined as = 0. If saturation O2 < 92 %, then would be defined as Unsuccessful = 1 . Continuous monitoring and recording of implementation Venturi mask FiO2 : 60%, 15L/min.	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Mobilization of accessory respiratory muscles with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation	Success would be defined as = 0 when there would be no mobilization of accessory respiratory muscles. Failure would be defined as = 1 when there would be recorded any mobilization and use of accessory respiratory muscles	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Mobilization of accessory respiratory muscles with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation	Success would be defined as = 0 when there would be no mobilization of accessory respiratory muscles. Failure would be defined as = 1 when there would be recorded any mobilzation and use of accessory respiratory muscles	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Mobilization of accessory respiratory muscles with Venturi mask, FiO2: 60%, 15L/min To record any use of accessory respiratory muscles with Venturi mask , FiO2: 60%, 15L/min	Success would be defined as = 0 when there would be no mobilization of accessory respiratory muscles. Failure would be defined as = 1 when there would be recorded any mobilzation and use of accessory respiratory muscles	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Comfort and tolerance of treatment with Visual Analogue Scale with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation	To monitor and record comfort of patient with the diagnostic tool of Visual Analogue Scale	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Comfort and tolerance of treatment with Visual Analogue Scale with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation	To monitor and record comfort of patient with the diagnostic tool of Visual Analogue Scale	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Comfort and tolerance of treatment with Visual Analogue Scale with Venturi mask , FiO2: 60%, 15L/min	To monitor and record comfort of patient with the diagnostic tool of Visual Analogue Scale	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)
Successful maintenance of Respiration rate within normal range (12-20/min) with Venturi mask , FiO2: 60%, 15L/min	Successful maintenance of Respiration rate within normal range (12-20/min) with Venturi mask , FiO2: 60%, 15L/min Continuous monitoring and recording of implementation of Venturi mask 60% fiO2, 15l/min	Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of Stay in the ICU	There will be recorded the total length of stay in the ICU since admission post surgery	Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge
Length of Stay in the Hospital	There will be recorded the total length of stay in the hospital since ICU admission	Post ICU admission period up to actual hospital discharge
Number of participants with death in the cardiothoracic ICU post extubation	There will be recorded the number of participants that will pass away post extubation in the ICU	Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge
Number of participants with death in the hospital post ICU discharge	There will be recorded the number of participants that will pass away post extubation in the hospital , after the ICU discharge	Post ICU discharge period up to actual hospital discharge
Number of participants with Atrial Fibrillation in the ICU post extubation	There will be recorded the number of participants that will present Atrial Fibrillation post extubation in the ICU	Post ICU admission period up to 48 hours or actual ICU discharge
Number of participants with any Adverse Events in the ICU	There will be recorded the number of participants that will present any Adverse Events (respiratory , non-respiratory) post extubation in the ICU	Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge
Number of participants with any Adverse Events in the Hospital	There will be recorded the number of participants that will present any Adverse Events (respiratory, non-respiratory) post extubation in the ICU, until hospital discharge.	Up to 1 month, or until actual hospital discharge
Percentage of participants presenting unsuccessful (failed) implementation of NHFO treatment	There will be recorded the number of participants that will present failure to comply with the treatment due to failing to maintain their respiratory parameters within normal range, or due to presenting intolerance and discomfort to the implementation of NHFO treatment	Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge
Number of participants with re-intubation in the ICU	There will be recorded the number of participants that will be re-intubated due to deterioration of their respiratory parameters.	Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge

Collaborators and Investigators

• Sponsor: National and Kapodistrian University of Athens
• Investigators: Study Chair: Spiros Zakynthinos, Professor, National and Kapodistrian University of Athens; Study Director: Spiridon Mentzelopoulos, AssProfessor, National and Kapodistrian University of Athens

Publications and helpful links

General Publications

• Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth. 2011 Dec;107(6):998-1004. doi: 10.1093/bja/aer265. Epub 2011 Sep 9.
• Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014 Aug 1;190(3):282-8. doi: 10.1164/rccm.201402-0364OC.
• Moller W, Feng S, Domanski U, Franke KJ, Celik G, Bartenstein P, Becker S, Meyer G, Schmid O, Eickelberg O, Tatkov S, Nilius G. Nasal high flow reduces dead space. J Appl Physiol (1985). 2017 Jan 1;122(1):191-197. doi: 10.1152/japplphysiol.00584.2016. Epub 2016 Nov 17.
• Stephan F, Barrucand B, Petit P, Rezaiguia-Delclaux S, Medard A, Delannoy B, Cosserant B, Flicoteaux G, Imbert A, Pilorge C, Berard L; BiPOP Study Group. High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. JAMA. 2015 Jun 16;313(23):2331-9. doi: 10.1001/jama.2015.5213.
• Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Beduneau G, Deletage-Metreau C, Richard JC, Brochard L, Robert R; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185-96. doi: 10.1056/NEJMoa1503326. Epub 2015 May 17.
• Fernandez R, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Masclans JR, Lesmes A, Panadero L, Hernandez G. High-flow nasal cannula to prevent postextubation respiratory failure in high-risk non-hypercapnic patients: a randomized multicenter trial. Ann Intensive Care. 2017 Dec;7(1):47. doi: 10.1186/s13613-017-0270-9. Epub 2017 May 2.
• Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond). 1989 Mar;76(3):277-82. doi: 10.1042/cs0760277.
• Pellegrini JA, Moraes RB, Maccari JG, de Oliveira RP, Savi A, Ribeiro RA, Burns KE, Teixeira C. Spontaneous Breathing Trials With T-Piece or Pressure Support Ventilation. Respir Care. 2016 Dec;61(12):1693-1703. doi: 10.4187/respcare.04816. Epub 2016 Sep 6.
• Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, Galia F, Futier E, Constantin JM, Jaber S. Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. Minerva Anestesiol. 2013 Dec;79(12):1344-55. Epub 2013 Jul 15.
• Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated Humidified High-Flow Nasal Oxygen in Adults: Mechanisms of Action and Clinical Implications. Chest. 2015 Jul;148(1):253-261. doi: 10.1378/chest.14-2871.
• Ritchie JE, Williams AB, Gerard C, Hockey H. Evaluation of a humidified nasal high-flow oxygen system, using oxygraphy, capnography and measurement of upper airway pressures. Anaesth Intensive Care. 2011 Nov;39(6):1103-10. doi: 10.1177/0310057X1103900620.
• Gotera C, Diaz Lobato S, Pinto T, Winck JC. Clinical evidence on high flow oxygen therapy and active humidification in adults. Rev Port Pneumol. 2013 Sep-Oct;19(5):217-27. doi: 10.1016/j.rppneu.2013.03.005. Epub 2013 Jul 8.
• Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. Br J Anaesth. 2009 Dec;103(6):886-90. doi: 10.1093/bja/aep280. Epub 2009 Oct 20.
• Groves N, Tobin A. High flow nasal oxygen generates positive airway pressure in adult volunteers. Aust Crit Care. 2007 Nov;20(4):126-31. doi: 10.1016/j.aucc.2007.08.001. Epub 2007 Oct 10.
• Parke RL, Eccleston ML, McGuinness SP. The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care. 2011 Aug;56(8):1151-5. doi: 10.4187/respcare.01106. Epub 2011 Apr 15.
• Parke RL, McGuinness SP. Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle. Respir Care. 2013 Oct;58(10):1621-4. doi: 10.4187/respcare.02358. Epub 2013 Mar 19.
• Chikata Y, Izawa M, Okuda N, Itagaki T, Nakataki E, Onodera M, Imanaka H, Nishimura M. Humidification performance of two high-flow nasal cannula devices: a bench study. Respir Care. 2014 Aug;59(8):1186-90. doi: 10.4187/respcare.02932.
• Hasani A, Chapman TH, McCool D, Smith RE, Dilworth JP, Agnew JE. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis. 2008;5(2):81-6. doi: 10.1177/1479972307087190.
• Moller W, Celik G, Feng S, Bartenstein P, Meyer G, Oliver E, Schmid O, Tatkov S. Nasal high flow clears anatomical dead space in upper airway models. J Appl Physiol (1985). 2015 Jun 15;118(12):1525-32. doi: 10.1152/japplphysiol.00934.2014.
• Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, Pesenti A. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017 May 1;195(9):1207-1215. doi: 10.1164/rccm.201605-0916OC.
• Lenglet H, Sztrymf B, Leroy C, Brun P, Dreyfuss D, Ricard JD. Humidified high flow nasal oxygen during respiratory failure in the emergency department: feasibility and efficacy. Respir Care. 2012 Nov;57(11):1873-8. doi: 10.4187/respcare.01575. Epub 2012 Mar 13.
• Frizzola M, Miller TL, Rodriguez ME, Zhu Y, Rojas J, Hesek A, Stump A, Shaffer TH, Dysart K. High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model. Pediatr Pulmonol. 2011 Jan;46(1):67-74. doi: 10.1002/ppul.21326. Epub 2010 Nov 23.
• Ferreyra G, Long Y, Ranieri VM. Respiratory complications after major surgery. Curr Opin Crit Care. 2009 Aug;15(4):342-8. doi: 10.1097/MCC.0b013e32832e0669.
• Dimick JB, Chen SL, Taheri PA, Henderson WG, Khuri SF, Campbell DA Jr. Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. J Am Coll Surg. 2004 Oct;199(4):531-7. doi: 10.1016/j.jamcollsurg.2004.05.276.
• Ji Q, Mei Y, Wang X, Feng J, Cai J, Ding W. Risk factors for pulmonary complications following cardiac surgery with cardiopulmonary bypass. Int J Med Sci. 2013 Sep 10;10(11):1578-83. doi: 10.7150/ijms.6904. eCollection 2013.
• Weissman C. Pulmonary complications after cardiac surgery. Semin Cardiothorac Vasc Anesth. 2004 Sep;8(3):185-211. doi: 10.1177/108925320400800303.
• Zarbock A, Mueller E, Netzer S, Gabriel A, Feindt P, Kindgen-Milles D. Prophylactic nasal continuous positive airway pressure following cardiac surgery protects from postoperative pulmonary complications: a prospective, randomized, controlled trial in 500 patients. Chest. 2009 May;135(5):1252-1259. doi: 10.1378/chest.08-1602. Epub 2008 Nov 18.
• Auriant I, Jallot A, Herve P, Cerrina J, Le Roy Ladurie F, Fournier JL, Lescot B, Parquin F. Noninvasive ventilation reduces mortality in acute respiratory failure following lung resection. Am J Respir Crit Care Med. 2001 Oct 1;164(7):1231-5. doi: 10.1164/ajrccm.164.7.2101089.
• Zhu GF, Wang DJ, Liu S, Jia M, Jia SJ. Efficacy and safety of noninvasive positive pressure ventilation in the treatment of acute respiratory failure after cardiac surgery. Chin Med J (Engl). 2013 Dec;126(23):4463-9.
• Nishimura M. High-Flow Nasal Cannula Oxygen Therapy in Adults: Physiological Benefits, Indication, Clinical Benefits, and Adverse Effects. Respir Care. 2016 Apr;61(4):529-41. doi: 10.4187/respcare.04577.
• Parke R, McGuinness S, Dixon R, Jull A. Open-label, phase II study of routine high-flow nasal oxygen therapy in cardiac surgical patients. Br J Anaesth. 2013 Dec;111(6):925-31. doi: 10.1093/bja/aet262. Epub 2013 Aug 6.
• Parke RL, McGuinness SP, Eccleston ML. A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients. Respir Care. 2011 Mar;56(3):265-70. doi: 10.4187/respcare.00801. Epub 2011 Jan 21.
• Zochios V, Klein AA, Jones N, Kriz T. Effect of High-Flow Nasal Oxygen on Pulmonary Complications and Outcomes After Adult Cardiothoracic Surgery: A Qualitative Review. J Cardiothorac Vasc Anesth. 2016 Oct;30(5):1379-85. doi: 10.1053/j.jvca.2015.12.023. Epub 2015 Dec 18. No abstract available.
• Esteban A, Alia I, Gordo F, Fernandez R, Solsona JF, Vallverdu I, Macias S, Allegue JM, Blanco J, Carriedo D, Leon M, de la Cal MA, Taboada F, Gonzalez de Velasco J, Palazon E, Carrizosa F, Tomas R, Suarez J, Goldwasser RS. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):459-65. doi: 10.1164/ajrccm.156.2.9610109. Erratum In: Am J Respir Crit Care Med 1997 Dec;156(6):2028.
• Godard S, Herry C, Westergaard P, Scales N, Brown SM, Burns K, Mehta S, Jacono FJ, Kubelik D, Maziak DE, Marshall J, Martin C, Seely AJ. Practice Variation in Spontaneous Breathing Trial Performance and Reporting. Can Respir J. 2016;2016:9848942. doi: 10.1155/2016/9848942. Epub 2016 Mar 29.
• 34. Vats, N., Singh, J., & Kalra, S. (2012). Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. Indian Journal of Physiotherapy
• Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs. 1989 Nov-Dec;14(6):323-5. doi: 10.1002/j.2048-7940.1989.tb01129.x.
• Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983 May;16(1):87-101. doi: 10.1016/0304-3959(83)90088-X.
• Adamis D, Dimitriou C, Anifantaki S, Zachariadis A, Astrinaki I, Alegakis A, Mari H, Tsiatsiotis N. Validation of the Greek version of Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Intensive Crit Care Nurs. 2012 Dec;28(6):337-43. doi: 10.1016/j.iccn.2012.02.003. Epub 2012 Mar 8.
• Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, Francis J, Speroff T, Gautam S, Margolin R, Sessler CN, Dittus RS, Bernard GR. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003 Jun 11;289(22):2983-91. doi: 10.1001/jama.289.22.2983.
• Lopez MG, Pandharipande P, Morse J, Shotwell MS, Milne GL, Pretorius M, Shaw AD, Roberts LJ 2nd, Billings FT 4th. Intraoperative cerebral oxygenation, oxidative injury, and delirium following cardiac surgery. Free Radic Biol Med. 2017 Feb;103:192-198. doi: 10.1016/j.freeradbiomed.2016.12.039. Epub 2016 Dec 27.
• Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, Hart RP, Dittus R. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001 Dec 5;286(21):2703-10. doi: 10.1001/jama.286.21.2703.
• Pun BT, Devlin JW. Delirium monitoring in the ICU: strategies for initiating and sustaining screening efforts. Semin Respir Crit Care Med. 2013 Apr;34(2):179-88. doi: 10.1055/s-0033-1342972. Epub 2013 May 28.
• 43. García, G., Agosta, M., Valencia, P., Mercedes, E., & Sarhane, Y. (2017). Avoiding confusion in high fl ow oxygen therapy concepts, 1-2
• Corley A, Rickard CM, Aitken LM, Johnston A, Barnett A, Fraser JF, Lewis SR, Smith AF. High-flow nasal cannulae for respiratory support in adult intensive care patients. Cochrane Database Syst Rev. 2017 May 30;5(5):CD010172. doi: 10.1002/14651858.CD010172.pub2.
• Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.

Study record dates

Study Major Dates

• Study Start (Actual): October 30, 2017
• Primary Completion (Actual): October 1, 2019
• Study Completion (Actual): October 17, 2019

Study Registration Dates

• First Submitted: August 1, 2017
• First Submitted That Met QC Criteria: September 12, 2017
• First Posted (Actual): September 14, 2017

Study Record Updates

• Last Update Posted (Actual): July 31, 2024
• Last Update Submitted That Met QC Criteria: July 29, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Respiratory Insufficiency
• Other Study ID Numbers: NKU Athens

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No